Pancreatic KRAS Vaccine Misses Its Primary Endpoint

Company Elicio Therapeutics Event Type Phase 2 readout and publication Modality Lymph-node-targeted mutant-KRAS peptide vaccine with CpG adjuvant Asset Camupepimut (ELI-002 7P) Target Mutant KRAS Disease Area KRAS-mutated pancreatic ductal adenocarcinoma (adjuvant) Summary Randomized Phase 2 AMPLIFY-7P did not meet its prespecified intent-to-treat disease-free survival…